



UNIVERSITY OF LEEDS

This is a repository copy of *Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/119692/>

Version: Supplemental Material

---

**Article:**

Lardas, M, Liew, M, van den Bergh, R et al. (21 more authors) (2017) Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. *European Urology*, 72 (6). pp. 869-885. ISSN 0302-2838

<https://doi.org/10.1016/j.eururo.2017.06.035>

---

(c) 2017, European Association of Urology. Published by Elsevier B.V. This manuscript version is made available under the CC BY-NC-ND 4.0 license  
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Table 1b: Baseline characteristics of prospective studies

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
<b>Bacon 2001<sup>a</sup> [14], USA, prospective, 1993-1998</b> <b>UCLA PCI</b>	Radical prostatectomy	421	68	Up to 60 months	T1: (0 %) T2: (95%) Unspecified: (0%) Missing: (5%)	2-4: (7%) 5 -6: (57%) 7-10: (29%) Missing: (7%)	NR	Heart disease (12%) High blood pressure (34%) High cholesterol (51%) Diabetes (5%) Stroke (1%) Arthritis (5%) Missing (2%)
	Radiotherapy	221	75		T1: (1%) T2: (84%) Unspecified: (5%) Missing: (10%)	2-4: (13%) 5 -6: (39%) 7-10: (28%) Missing:(19%)		Heart disease (24%) High blood pressure (48%) High cholesterol (50%) Diabetes (11%) Stroke (4%) Arthritis (8%) Missing (5%)
	Brachytherapy	69	71		T1: (1%) T2: (81%) Unspecified: (3%) Missing: (14%)	2-4: (13%) 5 -6: (51%) 7-10: (22%) Missing:(14%)		Heart disease (17%) High blood pressure (52%) High cholesterol (48%) Diabetes (0%) Stroke (4%) Arthritis (4%) Missing (9%)
<b>Barocas 2017<sup>b</sup> [30], USA, prospective, 2011-2012</b>	Radical prostatectomy	1523	61.5 {61.1-61.8}	40 [38-45]	T1c: 1140 (75%) T2: 380 (25%)	3+3: 744 (49%) 3+4: 458 (30%) 4+3: 170 (11%)	0-4: 334 (22%) 4.1-10: 1018 (67%) 10.1-20: 133 (9%)	Total Illness Burden Index 0-2: 481 (33%) 3-4: 624 (43%) ≥5: 343 (24%)

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
EPIC						8-10: 147 (10%)	>20: 38 (2%)	
	Radiotherapy	598	68.1 {67.6-68.7}		T1c: 436 (73%) T2: 161 (27%)	3+3: 210 (35%) 3+4: 201 (34%) 4+3: 86 (14%) 8-10: 99 (17%)	0-4: 85 (14%) 4.1-10: 394 (66%) 10.1-20: 86 (14%) >20: 33 (6%)	Total Illness Burden Index 0-2: 101 (17%) 3-4: 238 (41%) ≥5: 241 (42%)
Borchers 2004 [15], Germany, prospective, 1999-2004?  EORTC-QLQ-C30	Radical prostatectomy + NS	38	59.2 (4.6)	26 [12-60] *  *The study reports <u>only 12 months FU results</u>	T1c: 22 (58%) T2a: 16 (42%)	(2-4): 14 (38%) (5-6): 24 (62%)	6.4 (2.8)	NR
	Radical prostatectomy no NS	42	65.2 (4.9)		T1c: 19 (45%) T2a: 23 (55%)	(2-4): 18 (42%) (5-6): 24 (58%)	6.6 (2.6)	
	Brachytherapy	52	66.5 (6.0)		T1c: 23 (44%) T2a: 39 (56%)	(2-4): 21 (40%) (5-6): 31 (60%)	6.6 (2.6)	

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
<b>Evans 2015 [16], USA, prospective, patients for brachytherapy and IMRT were enrolled from 2003-2006 SBRT patients were enrolled from 2007-2011</b>  <b>EPIC</b>	Brachytherapy	262	65 (7.4)	24	T1: 221 (84%) T2:41 (16%)	2-6:206 (79%) 7:55 (21%) 8-10:1 (0.4%) N/A: 0	5.0 (2.8)	NR
	IMRT	160	69 (7.4)		T1: 128 (80%) T2:32 (20%)	2-6:99 (62%) 7:60 (38%) 8-10:1 (0.6%) N/A: 0	5.8 (4.2)	
	SBRT	381	70 (7.4)		T1:289 (76%) T2:92 (24%)	2-6:211 (55%) 7:164 (43%) 8-10:5 (1.3%) N/A: 1 (0.26%)	6.1 (3.9)	
<b>Jeldres 2015 [17], USA, prospective, 2007</b>  <b>EPIC</b>	Active Surveillance	77	65 (8.1)	27 (17)	T1a-T1c: 50 (65%) T2a: 27 (35%)	NR but inclusion criteria state that biopsy Gleason score: ≤6	4.0 (1.9)	0: 17 1: 21 ≥2: 39
	Radical Prostatectomy	228	58 (7.4)	36 (17)	T1a-T1c: 161 (71%) T2a: 67 (29%)		4.2 (1.9)	0: 56 1: 86 ≥2: 86

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
<b>Kobuke 2009 [18], Japan, prospective, 2004-2005</b>  <b>UCLA-PCI</b>	Radical prostatectomy	37	67 [54-75]	12	T1: 19 (51%) T2: 18 (49%)	6: 14 (38%) 7: 18 (49%) 8-9: 5 (13%)	8.31 [1.796-27.44]	NR
	Brachytherapy	36	67 [53-76]		T1: 17 (47%) T2: 19 (53%)	6: 21 (58%) 7: 7 (20%) 8-9: 8 (22%)	7.73 [1.13-74]	
<b>Malcolm 2010<sup>c</sup> [19], USA, prospective, 2000-2008</b>  <b>UCLA-PCI</b>	Open Radical prostatectomy	135	59 (7)	36	T1c or less: 112 (83%) T2a: 17 (13%) T2b+: 6 (4%) Unknown: 0	≤ 6: 93 (69%) 7: 34 (25%) ≥8: 8 (6%)	5.7 [4.7-7.3]	NR
	Robotic Radical prostatectomy	447	59 (6)		T1c or less: 340 (76%) T2a: 68 (15%) T2b+: 32 (7%) Unknown: 7 (2%)	≤ 6: 269 (60%) 7: 154 (34%) ≥8: 24 (5%)	5.2 [3.9-6.8]	
	Brachytherapy	122	66 (7)		T1c or less: 98 (80%) T2a: 16 (13%) T2b+: 3 (2%) Unknown: 5 (4%)	≤ 6: 88 (72%) 7: 28 (23%) ≥8: 6 (5%)	6.0 [4.5-8.2]	

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
<b>Namiki 2006 [20], Japan, prospective, 2004-2005</b>  <b>UCLA-PCI</b>	Radical prostatectomy	67	64.3 (6.5)	12	T1: 50 (75%) T2: 17 (25%)	≤6: 12 (18%) ≥7: 55 (82%)	8.8 (6.8)	NR
	Brachytherapy	70	67.0 (6.4)		T1: 56 (80%) T2: 14 (20%)	≤6: 47 (67%) ≥7: 23 (33%)	7.0 (3.4)	
<b>Pardo 2010 [21], Spain, prospective, 2003-2005</b>  <b>EPIC</b>	Radical prostatectomy	123	64.2 (5.5)	36	T1: 82 (67%) T2: 41 (33%) Unknown: 0	6.9 (6.4)	8.0 (3.3)	Number of chronic conditions 2.33 (1.5)
	External-beam radiotherapy	127	69.5 (5.4)		T1: 73 (57%) T2: 53 (42%) Unknown: 1 (1%)	5.9 (1.0)	8.2 (4.7)	Number of chronic conditions 2.5 (1.8)
	Brachytherapy	185	66.0 (7.0)		T1: 152 (82%) T2: 33 (18%) Unknown: 0	5.9 (5.3)	6.8 (2.1)	Number of chronic conditions 2.3 (1.6)
<b>Pinkawa 2009 [22], Germany, prospective, 2003-2006</b>  <b>EPIC</b>	Brachytherapy	52	68 [51–77]	16	≤T2a: 51 (98%)	<7: 50 (96%)	7 [1.5–14]	Hypertension: 11 (21%) Coronary heart disease: 6 (12%) Diabetes: 6 (12%) COPD: 4 (8%)

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
	External beam radiotherapy	52	68 [48–77]		≤T2a: 43 (83%)	<7: 39 (75%)	8 [2.5–24]	Hypertension: 11 (21%) Coronary heart disease: 13 (25%) Diabetes: 7 (14%) COPD: 6 (12)
<b>Punnen 2014<sup>d</sup> [25], USA, prospective, 1995-2011</b>  <b>UCLA-PCI</b>	NS Radical prostatectomy	1139	60.0 (6.8)	73 [51–100]	NR	NR	NR	none: 228 (20%) 1: 384 (34%) 2: 309 (28%) ≥3: 201 (18%)
	Non NS Radical prostatectomy	860	62.9 (6.6)	76 [51–103]				none: 148 (18%) 1: 249 (29%) 2: 226 (27%) ≥3: 224 (26)
	Brachytherapy	684	68.3 (7.2)	83 [52–104]				none: 61 (9%) 1: 168 (25%) 2: 202 (31%) ≥3: 233 (35%)
	EBRT	386	71.3 (6.2)	71 [48–100]				none: 31 (8%) 1: 85 (22%) 2: 110 (29%) ≥3: 155 (41%)

Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
<b>Resnick 2013 [26]/ Potosky 2004 [23]/ Potosky 2000 [24], USA, prospective, 1994-1995</b>  <b>PCOS questionnaire</b>	Radical prostatectomy	1164	64 [59–68]	180	T1: 377 (32.4%) T1/T2: 279 (24.0%) T2: 508 (43.6%)	2–4: 743 (64%) 5–7: 216 (18%) 8–10: 73 (7%) Unknown: 132 (11%)	<4: 122 (10%) 4–10: 703 (61%) >10: 339 (29%)	No. of coexisting illnesses 0: 513 1: 368 2: 179 ≥3: 104
	EBRT	491	69 [64–71]		T1: 150 (30.6%) T1/T2: 118 (24.1%) T2: 222 (45.3)	2–4: 292 (59%) 5–7: 110 (22%) 8–10: 46 (10%) Unknown: 43 (9%)	<4: 43 (9%) 4–10: 252 (56%) >10: 196 (35%)	No. of coexisting illnesses 0: 159 1: 160 2: 93 ≥3: 79
<b>Sanda 2008 [27], USA, prospective, 2003-2006</b>  <b>EPIC</b>	Radical prostatectomy	603	59 [38–79]	30	T1: 436 (72%) T2: 167 (28%)	<7: 371 (62%) 7: 207 (34%) >7: 25 (4%)	<4: 126 (21%) 4–10: 399 (66%) >10: 78 (13%)	Mean number of coexisting illnesses  0.9 (1.1)
	EBRT	292	69 [45–84]		T1: 202 (69%) T2: 90 (31%)	<7: 129 (44%) 7: 123 (42%) >7: 40 (14%)	<4: 46 (16%) 4–10: 177 (61%) >10: 69 (24%)	Mean number of coexisting illnesses  1.5 (1.2)



Study ID & year, country, design, recruitment period, PROM tool used	Interventions	N	Age: Mean (SD), median [range] {95% CI}	FU (months) Mean (SD), median [range]	T stage	Gleason score n or mean (SD)	PSA, n mean (SD) median [range]	Co-morbidity
	Brachytherapy	306	65 [44–84]		T1: 254 (83%) T2: 51 (17%)	<7: 227 (74%) 7: 76 (25%) >7: 2 (1%)	<4: 67 (22%) 4–10: 217 (71%) >10: 21 (7%)	Mean number of coexisting illnesses  1.3 (1.1)
<b>Schapira 2001<sup>a</sup> [28], USA, prospective, NR, UCLA-PCI</b>	Radical prostatectomy	42	64 [58-68]	12	T1: 55% T2: 45%	2-4: 30% 5-6: 49% 7: 19% 8-10: 3%	7.6 [4.9-11.1]	Charlson Comorbidity Index  0.57 (0.99)
	Radiotherapy	51	73 [68-75]		T1: 43% T2: 57%	2-4: 16% 5-6: 51% 7: 29% 8-10: 4%	7.1 [4.9-12.3]	Charlson Comorbidity Index  2.0 (2.1)
<b>Symon 2006 [29], USA, prospective, NR EPIC</b>	Radical prostatectomy	24	57.5 (7.7)	12	T1: 13 (56.5%) T2: 10 (43.5%)	2-6: 12 (50.0%) 7: 11 (45.8%) 8-10: 1 (4.2%)	4-10: 22 (91.6%) >10: 2 (8.3%)	NR
	EBRT	26	61.9 (27)		T1: 19 (76.0%) T2: 6 (24.0%)	2-6: 10 (38.5%) 7: 15 (57.7%) 8-10: 1 (3.9%)	4-10: 20 (76.9%) >10: 5 (19.2%)	

NR: not reported

a: Watchful waiting and hormonal arms of the study have been excluded from this review

b: Active surveillance arm of the study has been excluded from this review, as authors did not distinguish between watchful waiting, active surveillance, and treatment delay

c: Cryotherapy arm of the study has been excluded from this review

d: Watchful waiting/active surveillance and ADT arms of the study have been excluded from this review

e: Expectant management arm of the study have been excluded from this review